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Histone deacetylases (HDACs) are a family of enzymes involved in
the regulation of gene expression, DNA repair, and stress response.
These processes often are altered in tumors, and HDAC inhibitors
have had pronounced antitumor activity with promising results in
clinical trials. Here, we report the crystal structure of human HDAC8
in complex with a hydroxamic acid inhibitor. Such a structure of a
eukaryotic zinc-dependent HDAC has not be described previously.
Similar to bacterial HDAC-like protein, HDAC8 folds in a single 
domain. The inhibitor and the zinc-binding sites are similar in both
proteins. However, significant differences are observed in the
length and structure of the loops surrounding the active site,
including the presence of two potassium ions in HDAC8 structure,
one of which interacts with key catalytic residues. CD data suggest
a direct role of potassium in the fold stabilization of HDAC8.
Knockdown of HDAC8 by RNA interference inhibits growth of
human lung, colon, and cervical cancer cell lines, highlighting the
importance of this HDAC subtype for tumor cell proliferation. Our
findings open the way for the design and development of selective
inhibitors of HDAC8 as possible antitumor agents.
The epigenetic control of gene expression is operated througha series of posttranslational modifications of chromatin that
influence the electrostatics of DNA–protein interactions and
generate docking sites for a large number of chromatin-
interacting proteins (1, 2). The acetylation status of lysine
residues found in the accessible N termini of core histones is one
of the posttranslational chromatin modifications that impinge on
gene expression. Acetylation and deacetylation of histones are
controlled by the enzymatic activity of histone acetyltransferases
and histone deacetylases (HDACs) (3, 4). Alterations of gene
expression are a hallmark of cancer, and mounting evidence
suggests that at least a part of these alterations is mediated by
epigenetic mechanisms (5, 6). Importantly, the aberrant recruit-
ment of HDACs has been mechanistically linked to malignancy
in leukemias and lymphomas (7, 8), and small-molecule HDAC
inhibitors show antitumor activity in preclinical models and in
clinical trials and have the promise to become effective, new
antineoplastic therapeutics (9).
At least 18 HDAC subtypes exist, and they are subdivided into
three classes (10): class I (HDACs 1–3 and 8), homologous to the
yeast Rpd3 deacetylase; class II (HDACs 4–7, 9, and 10), related
to the yeast Hda1 deacetylase; and class III proteins (Sirtuins
1–7), which are yeast Sir2 homologs. HDAC11 has homology to
both class I and II enzymes but cannot unambiguously be
assigned to either class. Class I and II HDACs, as well as
HDAC11, are all zinc-dependent hydrolases. The therapeutically
relevant HDAC inhibitors are thought to be nonselective or
poorly selective inhibitors of all or most of class I and II enzymes
but do not inhibit class III HDACs (9). It is not clear whether the
antitumor properties of HDAC inhibitors are due to their lack
of specificity or are the consequence of targeting one or few
‘‘crucial’’ subtypes. This question is of considerable interest
because it may open the way for the development of novel, more
selective compounds, possibly with enhanced efficacy andor
tolerability.
Our understanding of the catalytic mechanism of HDACs and
inhibition by small molecules relies on the crystal structure of an
archeobacterial homolog of eukaryotic deacetylases (HDLP)
that is widely used as a model (11). The availability of structural
information on the molecular architecture of human HDACs
could have a significant impact on the design of subtype selective
inhibitors. Here, we report a previously undescribed structure of
a eukaryotic zinc-dependent HDAC, human HDAC8, com-
plexed with the hydroxamic acid inhibitor, N-hydroxy-4-
{methyl[(5-pyridin-2-yl-2-thienyl)sulfonyl]amino}benzamide
(Compound 1 in Table 1). We also show that HDAC8 is
important for the growth of human tumor cell lines and has a
distinct inhibition pattern that differs from that of HDAC1 and
-3, which both share 43% sequence identity with HDAC8. Our
findings open the way to the development of selective inhibitors
of this subtype as potential novel anticancer therapeutics.
Materials and Methods
Expression and Purification. The human HDAC8 gene was ex-
pressed and purified essentially as described in ref. 12, with
minor modifications (see Supporting Materials and Methods,
which is published as supporting information on the PNAS web
site). For details on human HDAC1 and -3, also see Supporting
Materials and Methods.
CD Spectroscopy. Spectra were collected by using a Jasco (Easton,
MD) J-710 spectropolarimeter (see Supporting Materials and
Methods).
Crystallization and Data Collection.For crystallization experiments,
130 MHDAC8 was incubated for 1 h at room temperature with
6.7 molar excesses of inhibitor. Crystals were grown after 1 week
at room temperature by the sitting-drop vapor-diffusion tech-
nique. Briefly, 4 l of protein solution in gel filtration buffer was
mixed with an equal volume of reservoir solution (0.1MMes, pH
5.31–5% polyethylene glycol 60002 mM Tris-2-carboxyethyl-
phosphine) and 0.4 l of 0.3 M glycyl-glycyl-glycine, and the
mixture was allowed to equilibrate against 600 l of reservoir
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solution. Data were collected at 100 K by using synchrotron
radiation (see Supporting Materials and Methods).
Structure Determination and Refinement. The structure was solved
by molecular replacement, using a truncated homology model,
residues 63–320 of HDAC8, based on the crystal structure of
HDLP in complex with trichostatin A (TSA) (11) (Protein Data
Bank ID code 1C3R). Model building and refinement were
performed with the programs QUANTA 2000 and CNX (both from
Accelrys, San Diego). The structure was refined to 2.5 Å with
final R and Rfree of 0.21 and 0.25, respectively. See Supporting
Materials and Methods, Table 2, and Fig. 7, which are published
as supporting information on the PNAS web site.
siRNA Transfection, Cell Growth, and Activity Assays. See Supporting
Materials and Methods.
Results and Discussion
RNA Interference. To examine the role of HDAC8 in cell prolif-
eration of tumor cells, we used RNA interference to disrupt
HDAC8 expression in three human tumor cell lines of different
origin (A549, HeLa, and HCT116). Two different short inter-
fering RNAs (siRNAs), both targeting HDAC8, inhibited cell
proliferation in all three cell lines. Data obtained with A549 cells
are shown in Fig. 1. A siRNA targeting Eg5, a mitotic kinesin
whose interference is known to cause mitotic arrest (Fig. 1B and
ref. 13), gave comparable growth inhibition to HDAC8 siRNAs,
whereas an unrelated siRNA (Luc) had no effect (Fig. 1 B and
C). HDAC8 recently was reported to associate specifically with
the inv(16) fusion protein found in acute myeloid leukemia, and
TSA has been shown to impair inv(16)-mediated repression (14).
From these data and our findings, we conclude that HDAC8
could have an important role in the physiology of solid or
hematologic tumors.
HDAC Inhibition. We next tested a panel of HDAC inhibitors on
class I HDACs 1, 3, and 8 (Table 1). Whereas HDACs 1 and 3
were inhibited by all of the inhibitors, HDAC8 was inhibited not
appreciably by apicidin or MS27-275 and to a much lower extent
than HDAC1 and -3 by suberoyl anilide hydroxamic acid
(SAHA) and TSA. Compound 1, an aryl hydroxamic acid
identified by screening a collection of small molecules, instead
showed relatively similar potencies (4-fold differences) on all
tested proteins. Thus, HDAC8 shows amore restricted inhibition
pattern than other class I enzymes, possibly indicating that it is
feasible to develop selective inhibitors of this subtype, whereas
development of inhibitors selective between more closely related
HDACs, such as HDAC1 and -3, may be more complicated. This
finding prompted us to attempt the cocrystallization of HDAC8
in the presence of compound 1 and to solve its three-dimensional
structure to a resolution of 2.5 Å.
Overall Structure. The overall structure of HDAC8 consists of two
molecules packed as a head-to-head dimer (Fig. 2A). Each
molecule binds one Zn2 ion and two K ions. The two
molecules are essentially identical (rms deviation 0.34 Å for the
C trace), forming a dimer interface that buries 1,300 Å2 of
molecular surface area. The dimeric arrangement in the crystal
is mediated by the inhibitor with the two capping groups (i.e.,
pyridine and thiophene moieties) of each inhibitor molecule
stacking against each other. This finding could well explain the
failure of our previous attempts to crystallize the apoprotein.
Furthermore, each capping group interacts with protein residues
Pro-273 and Tyr-306 of the opposite molecule, forming an
extensive hydrophobic sandwich and giving rise to the twofold
axis relating the two molecules in the asymmetric unit (Fig. 2A).
The oligomerization state observed in the crystal is unlikely to
occur in solution, because the results of size-exclusion chroma-
tography and light-scattering experiments are compatible with a
monomeric state for both the apoprotein and the protein–
inhibitor complex (data not shown). The structure of the
HDAC8monomer, similarly to the structure of HDLP (11) (30%
sequence identity, C rms deviation of 2.4 Å), forms a single
compact  domain composed of a central eight-stranded
parallel -sheet and 11 -helices (Fig. 2B). The twisted -sheet
(topology 2, -1, -3, -8, -7, -4, -5, and -6) is f lanked by five helices
on one side (topology 2, -10, -9, -8, and -11) and three helices
(topology 5, -6, and -7) on the other. Striking differences
between the two proteins are observed for most of the loops
Table 1. HDAC enzymatic inhibition
Compound
HDAC8
IC50, nM
HDAC1
IC50, nM
HDAC3
IC50, nM
TSA
490 1.5 0.6
SAHA
4,000 119 106
Compound 1
175.5 86.0 44
MS27–275
10,000 185 201
Apicidin
1,000 2 0.7
Fig. 1. Role of HDAC8 in cell proliferation of tumor cells. (A) Quantitative RT-PCR analysis of HDAC8 mRNA knockdown in A549 cells by an unrelated siRNA
(Luc) or two HDAC8-specific siRNAs (8.6 and 8.7). (B) Growth inhibition evaluated by [14C]thymidine incorporation. Luc siRNA was used as a negative control, and
Eg5 siRNA was used as a positive control. Each data set is the mean of triplicates. (C) The percentage of growth inhibition was normalized to the mock-transfected
negative control. The data reported are mean values from three independent experiments. Error bars indicate SD.
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emerging from the core of the protein, for the distal helices (1,
-3, and -4) and for the long extended loop (residues 325–356),
which connects helices 10 and -11. This region in HDAC8 is
completely different from that in HDLP, resulting in a large
change of the loop between residues 332 and 345, including the
loss of two helices (Fig. 2C). Overall, these variations give rise to
a more accessible active site in HDAC8. In particular, the loop
connecting 1 and -2 (residues 31–36) is shorter in HDAC8. In
addition, the loops connecting 5 and -6 (residues 202–212) and
7 and 9 (residues 265–279) are more open in HDAC8, giving
rise to a slightly deeper and larger pocket (Fig. 2C). Most
strikingly, the loop 332–345, part of the long extended linker
between 10 and -11, is 10 residues shorter than that observed
in HDLP, leaving the active site less shielded from one side,
which results in the lack of interactions between the protein and
the inhibitor capping group. It is conceivable that structural
variability in the loop regions emerging from the conserved core
will be found across the entire family of HDACs, possibly
reflecting the critical role of these regions in protein–protein
interactions or in conferring different substrate specificities to
individual members of the family.
Zinc-Binding Site. In the active site, the van der Waals surface of
the enzyme reveals an 12-Å-deep, narrow pocket likely to
accommodate the acetylated lysine during the catalytic reaction.
At the bottom of this tunnel, a Zn2 ion is found (Fig. 3). The
architecture of the active site and its immediate surroundings are
conserved between HDLP and HDAC8 and, based on sequence
homology, are likely to be common to all zinc-dependent
HDACs (Fig. 4). Similar to HDLP, the active site Zn2 ion of
HDAC8 is pentacoordinated, having Asp-178 (O1), His-180
(N1), and Asp-267 (O1) as ligands in addition to the hydrox-
amic acid group of the inhibitor (Fig. 3). Immediately below the
active site, a tube-like internal cavity filled by several water
molecules could act as shuttle for the reaction product acetate
(Fig. 5). In HDLP, this pocket has a different shape, by the effect
of numerous substitutions of buried residues that line out the
cavity (Figs. 4 and 5). Arg-37 and Cys-153, which are conserved
strictly in class I and II HDACs, could be hydrogen-bond
partners for the acetate byproduct of the hydrolysis reaction. In
addition, Arg-37 creates a positive electrostatic potential that
would be in accordance with binding the negatively charged
acetate ion. The release of the acetate and its exchange with the
bulk water could be accomplished by movements of the side
chains of Tyr-18, Tyr-20, and His-42, located in close proximity
to the external surface (Fig. 5). Ser-39, the target residue of
PKA-catalyzed phosphorylation of HDAC8, also is facing the
external surface of this cavity (Fig. 5). The phosphorylation of
Fig. 2. Overall HDAC8 structure. (A) Ribbon diagram of the asymmetric unit of human HDAC8 crystals. The two monomers, A and B, are shown in indigo and
yellow, respectively. The two inhibitor molecules and residues involved in the head-to-head packing are drawn in stick representation. Red, oxygen; blue,
nitrogen; orange, sulfur. Carbon is shown in indigo (molecule A) and yellow (molecule B). Violet spheres, Zn2 ions; red spheres, K ions. The chemical structure
of the hydroxamic acid inhibitor is drawn in the upper left. (B) Ribbon diagram of human HDAC8 monomer with -helices and -strands labeled and colored
yellow and indigo, respectively. The inhibitor is drawn in stick representation. Red, oxygen; blue, nitrogen; orange, sulfur; green, carbon. (C) Superposition of
human HDAC8 (yellow) and HDLP (gray) backbone. Compound 1 and TSA are drawn in stick representation. Oxygen, nitrogen, and sulfur are colored as in A.
Carbon is shown in yellow (compound 1) and gray (TSA). Dashed circles highlight structural variations of loops emerging from the core of the two structures.
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this residue was shown to inhibit HDAC8 enzymatic activity (15).
A negatively charged phosphate group in this position possibly
could impair the release of acetate, resulting in the decrease of
enzyme activity. Therefore, HDAC8 phosphorylation has con-
sequences opposite from those of the phosphorylation of other
class I HDACs (16).
Inhibitor-Binding Site.The structural characteristics of the hydrox-
amic acid inhibitor cocrystallized with HDAC8 are summarized
in Fig. 2A. It consists of a metal-binding domain, a linker
domain, and a hydrophobic capping group. The inhibitor coor-
dinates the zinc in a bidentate fashion and simultaneously
contacts residues likely to be involved in catalysis (His-142,
His-143, and Tyr-306) by its hydroxamate moiety (Fig. 3). In this
regard, the situation is very similar to that observed for the
inhibited structures of HDLP (11) and to zinc–metalloprotease–
hydroxamate complexes (17, 18). The cyclic linker region of the
inhibitor fits in the hydrophobic channel, with its aromatic aryl
moiety stacked between side chains of Phe-152 and -208. Ad-
ditional van der Waals interactions occur between the linker
region and the side chain of Met-274 and the main chain of
Gly-151. In the HDLP–TSA and HDLP–SAHA complexes (11),
the linker region of the two inhibitors is formed by a five- and
a six-carbon-long aliphatic chain, respectively. These chains act
as optimal linkers for the hydroxamic acid and the capping
group, allowing contacts both at the bottom and the entrance of
the pocket. Instead, inHDAC8–compound 1 complex, the linker
region is more involved in direct interactions with the hydro-
phobic pocket, and the pyridine moiety capping group does not
show any relevant interaction with the protein (Fig. 2 B and C).
Therefore, this group does not seem to contribute to the binding
affinity of the compound, given that the dimeric arrangement
seen in the crystal has not been found in solution. This obser-
vation should be true also for TSA and SAHA, both poor
HDAC8 inhibitors (Table 1), because the loop region featuring
the equivalent of Pro-22 from HDLP (Ala-32 in HDAC8), a
Fig. 3. Molecular surface representation and architecture of HDAC8 active
site. Residues relevant for catalysis and involved in inhibitor binding as well as
the inhibitor and the modeled acetyllysine are drawn in stick representation.
Red, oxygen; blue, nitrogen; orange, sulfur; gray, carbon. Carbon is colored
green for the inhibitor and wheat for the docked acetyllysine. Polar interac-
tions are shown as dashed yellow lines. Numbers in parentheses represent the
zinc-ligand distances.
Fig. 4. Multiple sequence alignment of selected deacetylases. The alignment encompasses the entire HDAC8 protein and residues 1–375 of HDAC1 (out of 482),
1–373 of HDLP (out of 375), and 643–1056 of HDAC4 (out of 1080). HDAC8 secondary structure and residue numbering are shown above the alignment. Red
vertical bar, identical residues; blue vertical bar, conserved residues; green vertical bar, residues coordinating Zn2 ion; filled violet circles, residues coordinating
K ions at site 1; open violet circles, residues coordinating K ions at site 2; black stars, residues contacting the inhibitor; black triangles, residues lining the internal
cavity.
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residue that interacts with the capping group of TSA inhibitor
(11), is shorter in HDAC8, and therefore this interaction is not
possible (Fig. 2C). A Pro is present in this position in all class I
and II HDACs, with the exception of HDAC10, which has an Ile,
suggesting that in most HDACs this loop region should be
structurally more similar to HDLP than to HDAC8. This finding
is in line with the increased potency of TSA and SAHA observed
on HDAC1 and -3 with respect to HDAC8. In HDAC8, the
increase in potency going from SAHA to TSA and compound 1
(Table 1) is correlated with a progressively bulkier linker region,
which maximizes hydrophobic interactions. All residues contact-
ing the linker are conserved except for Met-274, which is a Leu
in all other class I and II HDACs with the exception of HDAC10,
which has a Glu in this position. The lack of measurable
inhibition of HDAC8 by MS27-275, a compound that inhibits
both HDAC1 and -3 (Table 1), can be rationalized by the
presence of Trp-141 at the bottom of the tunnel (Fig. 6A), which
should impede an effective zinc chelation by the bulky metal
coordinating group, a N-(2-aminophenyl) formamide moiety, of
MS27-275. Trp-141 is replaced by Leu in HDAC1 and -3, which
should leave more space to accommodate this inhibitor and is in
line with the increased potency toward HDAC1 and -3.
Fig. 6A shows the molecular surface near the exit of the
channel. Three shallow pockets could be explored for the design
of more potent HDAC8 inhibitors. The capping group of the
inhibitor is oriented in the direction of pocket d, even if this
moiety does not interact with the protein but points toward the
solvent. An inhibitor with additional meta substituents in the aryl
moiety, with respect to the hydroxamic acid, could possibly
interact with pockets b and d, providing selective interactions in
addition to those in the channel. Further selectivity can be gained
by maximizing interactions of the inhibitor with pocket c and
with the loop region designated as ‘‘a’’ (Fig. 6A).
Potassium-Binding Site. Unexpectedly, the structure of HDAC8
reveals K ions bound at two sites: Site 1 is in close proximity (7.0
Å) to the zinc-binding site, whereas site 2 is located more toward
the periphery of the molecule, 15 Å away from site 1 (Fig. 6B).
The two sites were identified by strong positive peaks (19 and 13
, respectively) in the Fo Fc maps and had typical distances and
hexacoordination geometry for potassium binding (19). The
final concentration of K ions in the crystallization drop is 75
mM, a value lower than its intracellular physiological value of
150 mM, suggesting that the potassium-binding sites could be
biologically relevant. At site 1, the K ion is hexacoordinated by
six oxygen ligands from Asp-176 (main-chain carbonyl oxygen
and O1), Asp-178 (main-chain carbonyl oxygen), His-180
(main-chain carbonyl oxygen), Ser-199 (O), and Leu-200
(main-chain carbonyl oxygen), arranged in a distorted octahe-
dral geometry (Fig. 6B). Potassium-binding site 1 is directly
connected with the zinc-binding site, because the K ion is
coordinated by the main-chain carbonyl oxygens of Asp-178 and
His-180, whose side chains are involved in zinc chelation (Fig.
Fig. 5. Surface representation of the internal cavities of HDAC8 (yellow) and
HDLP (light blue). The ribbon diagram of the HDAC8 backbone is shown in
gray, and the water molecules found in the buried cavity of HDAC8 are shown
as cyan spheres. The inhibitor, ions, and several residues lining the cavity are
drawn in stick representation and colored as in Fig. 3.
Fig. 6. Inhibitor and potassium binding sites. (A) Closeup view of the molecular surface of HDAC8 at the active site entrance. The inhibitor is drawn in stick
representation and colored as in Fig. 3. Red, Ala-32; yellow, Asp-101; violet, Trp-141; orange, Met-274. Regions that could be explored for the design of more
potent HDAC8 inhibitors are labeled as a, b, c, and d. (B) Architecture of the two potassium-binding sites, K1 and K2. Residues coordinating K ions are drawn
in stick representation. Red, oxygen; gray, carbon; red spheres, K ions; cyan spheres, water molecules W1 and W2. Coordination bonds are drawn as dashed
yellow lines, and corresponding distances are reported in parentheses. The Fo Fc map (contoured at 10 ) is displayed around the K ions, which were omitted
for map calculation.
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4A). The presence of K in the active site can be expected to
influence the catalytic mechanism of the deacetylation reaction
in several aspects. First, its presence increases the positive
electrostatic potential in the active site and therefore could
contribute to stabilize the oxyanion formed in the transition
state of the deacetylation reaction andor to stabilize the
negatively charged acetate product. Furthermore, the K ion is
coordinated by Asp-176 bymeans of both backbone carbonyl and
side-chain oxygens (Figs. 4 and 6B). This coordination is ex-
pected to influence the correct orientation and chemical prop-
erties of Asp-176, a residue proposed to form a buried charge-
relay system with His-142 (11). By analogy to Ca2-binding
proteins (20), upon chelation with the cation, the two CO bonds
of the Asp-176 side chain no longer should be equivalent, with
the bond of the chelating oxygen having more single-bond
character and that of the nonchelating oxygen, hydrogen-bonded
to His-142, more double-bond character. Therefore, the pres-
ence of potassium at site 1 should have a direct effect on the pK
value of His-142, possibly facilitating its deprotonation after
product release. Residues at potassium-binding site 1 are con-
served in all zinc-dependent HDACs, with the exception of
Leu-200, which can be substituted with Phe (HDAC1, -2, and -3)
or Trp (HDAC10). Potassium-binding site 2 (Fig. 6B) is formed
by the main-chain carbonyl oxygen of residues Phe-189, Thr-192,
Val-195, and Tyr-225 and two water molecules. The relevance of
this site for the catalytic activity of the enzyme is not obvious
from the structure. It could help to maintain a specific protein
conformation. The sequence conservation at this site is some-
what lower than at site 1: Thr-192 is Asp in class II HDACs;
Val-195 is different only in HDAC9 (Ile); and Tyr-225 is
different only in HDAC10 (Phe). The two potassium-binding
sites are placed on the same face of the -sheet and contribute
equally to anchoring helix 7 and its loops to the central -sheet
(Fig. 6B). Residues forming the two potassium-binding sites
come from loops contiguous to helix 7 (Asp-178 and His-180 at
site 1; Phe-189 and Thr-192 at site 2) and from strands 4, -5, and
-6 (Asp-176, Ser-199, and Leu-200 at site 1; Val-195 and Tyr-225
at site 2).
CD Spectroscopy.To further support the importance of the K ion
to the structure, we have investigated the thermal unfolding of
HDAC8 in solutions containing KCl or NaCl by CD spectros-
copy. The melting midpoint of the secondary structure in a
buffer containing NaCl was lower than that measured in the
presence of KCl (Tm  35.5°C vs. Tm  41°C) (Fig. 8, which is
published as supporting information on the PNASweb site). This
finding suggests, in accordance with the structure, that K ions
are required for the structural stability of HDAC8. The exchange
with Na ions, which share with K the same external electronic
configuration but a remarkably smaller ionic radius, could alter
the overall folding of the enzyme, in agreement with the
decreased protein stability observed when the protein was
purified in the presence of NaCl (data not shown). The finding
of a direct involvement of K ions in the architecture of the
active site and in the stabilization of structural elements of
HDAC8 could rationalize previously observed potassium de-
pendence of the activity of this enzyme (12) and of other
subtypes (P.G., unpublished results). Furthermore, the conser-
vation of potassium-binding residues in zinc-dependent HDACs
suggests that the presence of these metal ions could be relevant
for the whole family of enzymes.
Note Added in Proof. While this work was under review, a paper by
Somoza et al. (21) was published. The authors describe the structure of
human HDAC8 with four inhibitors. Their structures are comparable to
ours.
We thank Dominique Bourgeois for assistance in the data collection at
beamline ID14-H3, European SynchrotronRadiation Facility, Grenoble,
France; Michael Goetz (Merck, Rahway, NJ) for providing Apicidin; and
Philip Jones (Istituto di Ricerche di Biologia Molecolare P. Angeletti)
and Sylvie Bourrain (Merck, Harlow, U.K.) for providing the other
HDAC inhibitors. This work was supported in part by a grant from the
Ministero dell’Istruzione, dell’Universita`, e della Ricerca.
1. Wolffe, A. P. & Guschin, D. (2000) J. Struct. Biol. 129, 102–122.
2. Jenuwein, T. & Allis, C. D. (2001) Science 293, 1074–1080.
3. Kurdistani, S. K. & Grunstein, M. (2003) Nat. Rev. Mol. Cell Biol. 4,
276–284.
4. Hassig, C. A. & Schreiber, S. L. (1997) Curr. Opin. Chem. Biol. 1, 300–308.
5. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. (2004) Nature 429, 457–463.
6. Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M.,
Weijenberg, M. P., Herman, J. G. & Baylin, S. B. (2002) Nat. Genet. 31,
141–149.
7. Kramer, O. H., Gottlicher, M. & Heinzel, T. (2001) Trends Endocrinol. Metab.
12, 294–300.
8. Lee, S. C., Bottaro, A. & Insel, R. A. (2003) Mol. Immunol. 39, 923–932.
9. Johnstone, R. W. (2002) Nat. Rev. Drug Discovery 1, 287–298.
10. Gregoretti, I. V., Lee, Y. M. & Goodson, H. V. (2004) J. Mol. Biol. 338,
17–31.
11. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V.M., Rifkind, R. A., Marks,
P. A., Breslow, R. & Pavletich, N. P. (1999) Nature 401, 188–193.
12. Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G. F.,
Johanson, K., Sung, C. M., Liu, R. & Winkler, J. (2000) J. Biol. Chem. 275,
15254–15264.
13. Weil, D., Garcon, L., Harper, M., Dumenil, D., Dautry, F. & Kress, M. (2002)
BioTechniques 33, 1244–1248.
14. Durst, K. L., Lutterbach, B., Kummalue, T., Friedman, A. D. & Hiebert, S. W.
(2003) Mol. Cell. Biol. 23, 607–619.
15. Lee, H., Rezai-Zadeh, N. & Seto, E. (2004) Mol. Cell. Biol. 24, 765–773.
16. Galasinski, S. C., Resing, K. A., Goodrich, J. A. & Ahn, N. G. (2002) J. Biol.
Chem. 277, 19618–19626.
17. Nishino, N. & Powers, J. C. (1978) Biochemistry 17, 2846–2850.
18. Kam, C. M., Nishino, N. & Powers, J. C. (1979) Biochemistry 18, 3032–3038.
19. Harding, M. M. (2002) Acta Crystallogr. D 58, 872–874.
20. Mizuguchi, M., Nara, M., Kawano, K. & Nitta, K. (1997) FEBS Lett. 417,
153–156.
21. Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J.,
Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) Structure 7, 1325–1334.
Vannini et al. PNAS  October 19, 2004  vol. 101  no. 42  15069
BI
O
CH
EM
IS
TR
Y
